Home > Haematology > FDA withdraws approval for TG Therapeutics cancer treatment

FDA withdraws approval for TG Therapeutics cancer treatment

Reuters - 01/06/2022 - The U.S. Food and Drug Administration said on Wednesday it has withdrawn its approval for TG Therapeutics Inc's lymphatic cancer treatment Ukoniq over concerns of higher risk of death in patients receiving the drug. Ukoniq received accelerated approval in the United States in February last year to treat adult patients with marginal zone lymphoma who have received prior therapy and for the treatment of adult patients with follicular lymphoma. The U.S. health regulator has rarely withdrawn approval for treatments, but has recently done so for drugs approved under its "accelerated approval" pathway. The pathway, mainly for rare diseases or small patient populations that have had no effective treatments, has come under increasing scrutiny after the FDA used it last year to approve Biogen Inc's controversial Alzheimer's Disease drug despite efficacy concerns. The U.S. health regulator said based on updated clinical trial data it has d...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on